# An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

> **NCT00002205** · NA · COMPLETED · sponsor: **Glaxo Wellcome**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Abacavir sulfate
- **DRUG:** Amprenavir

## Key facts

- **NCT ID:** NCT00002205
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002205, "An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*